F42.0 F42.1 F42.2
Conditions
Interventions
Group 1: Patients with OCD will receive one session of verum tDCS and one session of sham tDCS over the medial frontal cortex (cathode over FCz, anode on right cheek) for 20 minutes at an intensity of
Sponsors
Humboldt-Universität zu Berlin
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: - Inclusion criterion for patients: Primary diagnosis of obsessive-compulsive disorder (ICD-10, F42.-) as assessed by the Structured Clinical Interview for DSM-V Axis I Disorders - German as native language - Ability to provide written informed consent
Exclusion criteria
Exclusion criteria: - Current or lifetime diagnosis of a substance-related disorder, schizophrenia spectrum disorder, delusional disorder, bipolar disorder, neurological disorder of the CNS - Verbal IQ < 85 - Uncorrectable visual, auditory, or motor impairments - Benzodiazepines within the last week, neuroleptics during the last three months - Contraindications for transcranial direct current stimulation: any metal or electronic implants in the head or upper body (e.g., cochlear implant, brain stimulator, aneurysm clip or stent, cardiac pacemaker), skin disorder or skin condition at or near stimulation locations (e.g., psoriasis or eczema), pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Performance monitoring: - Behavioral performance (reaction time and accuracy) and event-related potentials (ERN, Pe, CRN) during the flanker task at session 1 and session 2 Affective evaluation of self-generated actions: - Behavioral performance (reaction time and accuracy) and event-related potentials (ERN, Pe, CRN) during the evaluative go/no-go task (go/no-go task combined with an affective word categorization task) at session 1 and session 2 - Skin conductance response and heart rate during the flanker task and the evaluative go/no-go task at session 1 and session 2 | — |
Secondary
| Measure | Time frame |
|---|---|
| Response inhibition: - Behavioral performance (reaction time and accuracy) and event-related potentials (N2, P3) during the evaluative go/no-go task at session 1 and session 2 Questionnaires measuring personality traits related to inter-individual differences in electrophysiological correlates of performance monitoring to explore potential moderating effects on primary outcomes: - Severity of OCD symptoms, assessed by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) (only assessed in patients with OCD) - Severity of depressive symptoms, assessed by the Montgomery Åsberg Depression Rating Scale (MADRS) (only assessed in patients with OCD) - Obsessive-compulsive symptoms, assessed by the Obsessive-Compulsive Inventory-Revised (OCI-R) - Depressive symptoms, assessed by the Beck Depression Inventory II (BDI-II) - Harm avoidance, assessed by the Temperament and Character Inventory (TCI, scale harm avoidance) - State and trait anxiety, assessed by the State and Trait Anxiety Inventory (STAI) - Generalized worry, assessed by the Penn State Worry Questionnaire (PSWQ) - Perfectionism, assessed by the Frost Multidimensional Perfectionism Scale (FMPS) - Positive and negative affect, assessed by the Positive and Negative Affect Scale (PANAS) - Neuroticism and conscientiousness, assessed by the NEO Five-Factor Inventory (NEO-FFI, scales neuroticism and conscientiousness) - Behavioral activation system and behavioral inhibition system sensitivity, assessed by the Behavioral Inhibition System/Behavioral Approach System (BIS/BAS) scales | — |
Countries
Germany
Contacts
Public ContactLuisa Balzus
Berlin School of Mind and Brain, Humboldt-Universität zu Berlin
Outcome results
None listed